NCT04718805View on ClinicalTrials.gov

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 26, 2021

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions
Healthy
Interventions
DRUG

Darunavir

Participants will receive a single dose of Darunavir tablets orally as per assigned treatment sequence.

DRUG

Cobicistat

Participant will receive a single dose of Cobicistat tablets orally as per assigned treatment sequence.

DRUG

Darunavir/Cobicistat FDC

Participants will receive a single dose of darunavir and cobicistat FDC tablets orally as per assigned treatment sequence.

Trial Locations (1)

2060

SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerp

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04718805 - A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions | Biotech Hunter | Biotech Hunter